‹ Back
Survodutide
What it helps
The liver, body fat, energy use, and blood sugar.
Sources
Read the original sources
- Survodutide in MASH and liver fibrosis, Sanyal 2024, NEJM (Abstract · checked 2026-10-13)
- Shared mechanistic pathways of glucagon signalling in obesity and fatty liver, Neff 2025, Diabetes Obes Metab (Abstract · checked 2026-10-13)
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity, dose-finding, le Roux 2024, Lancet Diabetes Endocrinol (Abstract · checked 2026-10-13)
- SYNCHRONIZE-1: survodutide phase 3 (le Roux and colleagues · 2026 · Published abstract · checked 2026-10-08)
- BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. (Zimmermann · 2022 · Abstract; full methods not assumed · checked 2026-10-13)
- The mechanism of action of oxyntomodulin in the regulation of obesity, Wynne 2010 (Abstract · checked 2026-10-13)
- Type 2 diabetes and obesity: the present and future of incretin therapy, Shestakova and Bashlykova 2025, Therapeutic Archive (Russia) (Summary · checked 2026-10-13)